BrainsWay Ltd. (NASDAQ:BWAY - Free Report) - Investment analysts at HC Wainwright boosted their Q2 2025 EPS estimates for shares of BrainsWay in a research note issued to investors on Tuesday, May 27th. HC Wainwright analyst R. Selvaraju now expects that the company will earn $0.05 per share for the quarter, up from their previous estimate of $0.04. HC Wainwright has a "Buy" rating and a $16.00 price target on the stock. The consensus estimate for BrainsWay's current full-year earnings is $0.08 per share. HC Wainwright also issued estimates for BrainsWay's FY2025 earnings at $0.19 EPS.
BrainsWay Trading Down 1.2%
BrainsWay stock traded down $0.12 during midday trading on Thursday, hitting $10.31. The stock had a trading volume of 21,175 shares, compared to its average volume of 68,147. The firm's fifty day moving average is $9.23 and its two-hundred day moving average is $9.72. The company has a market capitalization of $194.57 million, a PE ratio of 103.11 and a beta of 1.25. BrainsWay has a 52-week low of $5.67 and a 52-week high of $11.79.
BrainsWay (NASDAQ:BWAY - Get Free Report) last released its earnings results on Tuesday, May 13th. The company reported $0.04 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.02 by $0.02. The company had revenue of $11.54 million during the quarter, compared to analyst estimates of $11.45 million. BrainsWay had a net margin of 3.88% and a return on equity of 3.52%.
Institutional Inflows and Outflows
Several hedge funds and other institutional investors have recently added to or reduced their stakes in BWAY. JPMorgan Chase & Co. boosted its stake in BrainsWay by 316.3% in the 3rd quarter. JPMorgan Chase & Co. now owns 14,769 shares of the company's stock worth $136,000 after purchasing an additional 11,221 shares during the period. Rhumbline Advisers boosted its stake in BrainsWay by 10.8% in the 4th quarter. Rhumbline Advisers now owns 21,966 shares of the company's stock worth $207,000 after purchasing an additional 2,144 shares during the period. ARK Investment Management LLC bought a new position in BrainsWay in the 4th quarter worth approximately $1,656,000. Sei Investments Co. bought a new position in BrainsWay in the 4th quarter worth approximately $149,000. Finally, Phoenix Financial Ltd. boosted its stake in BrainsWay by 100.8% in the 4th quarter. Phoenix Financial Ltd. now owns 482,724 shares of the company's stock worth $4,552,000 after purchasing an additional 242,366 shares during the period. 30.11% of the stock is currently owned by institutional investors.
About BrainsWay
(
Get Free Report)
BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases.
Featured Stories
Before you consider BrainsWay, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and BrainsWay wasn't on the list.
While BrainsWay currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
